October 28, 2013 / 2:51 PM / 4 years ago

MARKET PULSE-Gogo, Fusion-io, NQ Mobile, Lifevantage, Glu, Petrobras

(For more market insights, including options activity, click on ; for the Day Ahead newsletter link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s)

Oct 28 (Reuters) - U.S. stocks were little change on Monday as investors found few reasons to keep pushing shares higher after the S&P 500 climbed to a series of records on expectations for continuing Federal Reserve stimulus. The Dow Jones industrial average was down 0.11 percent at 15,552.68, the S&P 500 was hardly changed 1,759.75 and the Nasdaq Composite was down 0.09 percent at 3,939.94.

** GOGO INC, $16.78, up 3.3 pct (10:14 a.m. ET)

The in-flight internet connectivity provider said it has signed a contract to offer internet services on Japan Airlines’ entire domestic fleet, comprising 77 aircraft.

** FUSION-IO INC, $10.76, up 13 pct (10:24 a.m. ET)

Chief Executive Shane Robison bought 105,500 shares of the company on Friday, according to a regulatory filing. This was the first time that Robison, who became CEO in May, bought shares in the company. “I am not aware of the old CEO - David Flynn - ever purchasing shares,” Piper Jaffray analyst Andrew Nowinski said.

** GLU MOBILE INC, $3.58, up 4.7 pct (10:41 a.m. ET)

The mobile game maker’s “Deer Hunter” game, launched last month, has exceeded performance expectations, and could lead the company to raise its forecast for 2013, Benchmark Co analyst Mike Hickey wrote in a note. The company will report third-quarter results on Wednesday.

** LIFEVANTAGE CORP, $2.28, down 12 pct (10:36 a.m. ET)

The nutritional products maker priced a dutch auction tender offer for up to $40 million of its common shares at $2.45 per share, which was at the low end of its projected range of $2.45-$2.80 per share and below the stock’s Friday close of $2.59.

** PETROLEO BRASILEIRO SA, $16.73, up 5 pct (10:00 a.m. ET)

The cost of developing the giant offshore Libra oil field will not delay other projects in the portfolio of Brazil’s state-run oil company, Director of Exploration Jose Formigli Filho said on a phone conference. The company said on Friday that it was discussing a new fuel price methodology in order to better align domestic prices with those abroad. {ID:nE5N0F705H]

** ONCOGENEX PHARMACEUTICALS INC, $7.84, up 9 pct (10:11 a.m. ET)

Needham & Co analyst Chad Messer upgraded his rating on cancer drug developer’s stock to “strong buy” from “buy,” saying its prostate cancer drug which is currently being tested in combination with chemotherapy generic docetaxel in a mid-stage trial, has a high chance of success.

** KIRBY CORP, Friday close $90.50, up 2 pct premarket

The barge operator reported a 30 percent rise in third-quarter profit and also said it expects higher earnings for the fourth quarter due to strong demand, better utilization levels and higher pricing in the marine transportation markets.

** CLOVIS ONCOLOGY INC, $62.04, up 10.3 pct (9:46 a.m. ET)

The cancer drug developer said on Sunday that interim data from an early-stage trial on its experimental lung cancer drug showed evidence of tumor shrinkage and was well-tolerated with no evidence of rash or dose-related diarrhea.

** CROCS INC, $13.06, down 4.5 pct (9:47 a.m. ET)

Brokerage Piper Jaffray cut its rating on the shoe maker’s stock to “neutral” from “overweight,” TheFlyOnTheWall.com reported.

** ALLIANCE RESOURCE PARTNERS LP, $75.52, down 1 pct (9:48 a.m. ET)

The coal miner said it expects full-year profit, revenue and coal output to be near the lower end of its earlier forecast due to unexpected disruption of production at its Onton mine in the Illinois basin.

** CONSOL ENERGY INC, $37.42, down 1.7 pct (9:49 a.m. ET)

The company, founded during the U.S. Civil War, said it will sell five West Virginia coal mines to privately held Murray Energy Corp amid regulatory uncertainty and as it focuses more on growing its natural gas operations.

** CF INDUSTRIES HOLDINGS INC, $218.07, up 4 pct (9:49 a.m. ET)

** MOSAIC CO, $46.79, up 1.9 pct (9:50 a.m. ET)

Mosaic said it would buy the phosphate business of the fellow U.S. fertilizer company for $1.2 billion in cash.

** TENNECO INC, $54.44, up 2.9 pct (9:50 a.m. ET)

The auto parts maker reported third-quarter results above analysts’ expectations as strong vehicle sales in the United States boosted demand for parts.

** TRIMAS CORP, $41.53, down 0.8 pct (9:51 a.m. ET)

The company, which makes packaging equipment, gaskets and aerospace fasteners, reported third-quarter profit above analysts’ expectations as it got a boost from recent acquisitions and the company raised its sales forecast for 2013.

** DARA BIOSCIENCES INC, $0.51, up 1 pct (9:51 a.m. ET)

The pharmaceutical company expanded its sales force catering to the U.S. oncology market through an agreement with Alamo Pharma Services, a unit of privately held Mission Pharmacal. Dara said it expects to have the sales force trained and in the field by Jan. 1.

** ANACOR PHARMACEUTICALS INC, $13.05, up 1.5 pct (9:52 a.m. ET)

The company will get $142.5 million from Canada’s Valeant Pharmaceuticals International Inc after the companies settled intellectual property-related disputes.

** BRISTOL-MYERS SQUIBB CO, $51.00, up 4.6 pct (9:52 a.m. ET)

Analysts at Morgan Stanley raised their rating on the drugmaker’s stock to “overweight” from “equal weight,” according to theflyonthewall.com.

** MYRIAD GENETICS INC, $25.81, up 1.2 pct (9:52 a.m. ET)

The molecular diagnostics company said validation data demonstrated the company’s lung cancer test significantly predicted patients’ risk of death from early-stage lung adenocarcinoma, a form of lung cancer, within five years of being diagnosed.

** BOARDWALK PIPELINE PARTNERS LP, $30.96, down 1 pct (9:53 a.m. ET)

The midstream master limited partnership reported a lower-than-expected profit for the third quarter, hurt by a fall in revenue for its services due to a reduction in the level of natural gas price spreads over time.

** BIOGEN IDEC, $259.70, up 3 pct (9:53 a.m. ET)

The company reported $286 million in third-quarter sales of its high-profile new multiple sclerosis drug, Tecfidera, providing fresh evidence that the medicine is off to an impressive launch and exceeding expectations.

** MERCK & CO INC, $45.52, down 2.2 pct (9:54 a.m. ET)

The drugmaker reported better-than-expected third-quarter earnings on Monday thanks to cost cutting, but lower sales of its Januvia diabetes treatment added fresh evidence its biggest product was losing ground to newer drugs.

** BURGER KING WORLDWIDE INC, $20.84, up 5.5 pct (9:54 a.m. ET)

The fast-food chain known for its Whopper hamburgers reported a better-than-expected third-quarter profit as it slashed costs by franchising more outlets and sales grew outside North America.

** AMC NETWORKS INC, $68.61, down 2.5 pct (9:55 a.m. ET)

** LIBERTY MEDIA CORP, $150.70, down 0.5 pct (9:55 a.m. ET)

The cable television network said it would buy Chellomedia, the international content unit of John Malone’s Liberty Global Plc, for about $1.04 billion, giving it greater control over the global distribution of its programs.

** NQ MOBILE INC, $12.18, up 14.6 pct (9:57 a.m. ET)

The Chinese mobile security software company labelled a “massive fraud” by Muddy Waters Research Group, hit back on Friday by releasing details of its bank accounts and threatening legal action.

** ZOGENIX INC, $3.28, up 8 pct (9:58 a.m. ET)

The specialty pharmaceutical company said on Friday that the U.S. Food and Drug Administration approved its drug for treating pain severe enough to require around-the-clock, long-term treatment.

William Blair analyst Tim Lugo raised his price target on the company’s stock to $6 from $3, saying that the drug had a substantial opportunity in the market for chronic pain drugs.

“If we assume a relatively conservative $7 per day and an average 25 days of therapy, only a 1 percent penetration into the combination market would suggest a $245 million product,” he wrote in a note to clients.

** DENDREON CORP, $2.90, up 14.4 pct (9:58 a.m. ET)

The drug maker is looking for a suitor after sales for its lead product, prostate cancer drug Provenge, were weaker than expected, according to a Bloomberg report.

** HAEMONETICS CORP, $40.37, down 1 pct (9:58 a.m. ET)

The company, which provides devices, information management and consulting services related to the collection and transfusion of blood, reported better-than-expected adjusted second-quarter earnings of 66 cents per share, fueled by a 14 percent rise in sales of its plasma collection devices in North America

** ROPER INDUSTRIES INC, $127.06, down 4.5 pct (9:59 a.m. ET)

The company, which makes radio frequency and medical and scientific imaging products, forecast current-quarter profit below analysts’ estimates, saying it expects growth in the energy industry and some other markets to be slower-than-expected. (Compiled by Sampad Patnaik; Editing by Joyjeet Das)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below